The Drug Regulatory Authority of Pakistan (DRAP) has issued a nationwide voluntary recall of two widely prescribed antibiotics Amoxil Forte Suspension 250mg and Amoxil Suspension 125mg by GlaxoSmithKline Pakistan Ltd (GSK) after defective seals and capping issues were found in 58 and 111 batches, respectively. DRAP’s August 5 alert warns the flaw could compromise product sterility, risking contamination and reduced effectiveness. The recall follows GSK’s own report of the defect, with DRAP directing hospitals, pharmacies, and distributors to locate and return affected stocks immediately. Healthcare providers and the public are urged to stop use, return products, or report via DRAP’s complaint portal a swift move aimed at safeguarding patient safety nationwide.